Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

Table 1

Common adverse events associated with the incretin therapies other than hypoglycaemia: exenatide, liraglutide, sitagliptin, saxagliptin, and linagliptin, adapted from [60].

GLP-1 receptor agonists	Adverse events
Exenatide	Nausea, diarrhoea, vomiting, feeling jittery, dizziness, headache, and dyspepsia
Liraglutide	Nausea, diarrhoea, and headache
DPP-4 inhibitors
Sitagliptin	Upper respiratory tract infection, nasopharyngitis, and headache
Saxagliptin	Upper respiratory tract infection, urinary tract infection, and headache
Linagliptin	Headache, joint pain, and sore throat
Linagliptin and metformin	Cough, decreased appetite, nausea, headache, sore throat, vomiting, and diarrhoea